The potential roles for novel biomarkers in rheumatoid arthritis assessment

Clinical and Experimental Rheumatology

Volumn 29, Issue 3, 2011, Pages 567-574

  Mease, Philip J ^a,b  

^a Swedish Medical Center   (Sweden)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Immune monitoring; Rheumatoid arthritis

Indexed keywords

AGGRECAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLYCOPROTEIN GP 39; HLA DR ANTIGEN; HLA DR4 ANTIGEN; HYALURONIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METHOTREXATE; PREDNISONE; PYRIDINOLINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RHEUMATOID FACTOR; SERUM AMYLOID A; STEROID; STROMELYSIN; SULFALAZINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; AUTOANTIBODY;

CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; X RAY; GENETIC MARKER; HOSPITALIZATION; METABOLISM; METHODOLOGY; MONITORING;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENETIC MARKERS; HUMANS; INFLAMMATION MEDIATORS; MONITORING, PHYSIOLOGIC; SEVERITY OF ILLNESS INDEX;

EID: 80052041108     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. ALAMANOS Y, VOULGARI, P, DROSOS A: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36: 182-8.
2. KVIEN TK: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22 (Suppl. 2): 1-12.
3. FEELY MG, ERICKSON A, O'DELL JR: Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother 2009; 10: 2095-106.
4. ISAACS JD: Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther 2009; 9: 1463-75.
5. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancer 1999; 354: 1932-9.
6. CROWSON CS, MYASOEDOVA E, MATTESON EL, KREMERS HM, THERNEAU TM, GABRIEL SE: Has survival increased in patients diagnosed with rheumatoid arthritis? Programs and abstracts of the 2009 ACR/ ARHP Annual Meeting; October 21, 2009; Philadelphia, PA. Abstract 1172.
7. GABRIEL SE, CROWSON CS, O'FALLON WM: Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26: 2529-33.
8. KATCHAMART W, BOMBARDIER C: Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol 2010; 37: 1411-5.
9. BAKKER MF, JACOBS JW, VERSTAPPEN SM, BIJLSMA JW: Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007; 66 (Suppl. III): iii56-iii60.
10. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.: T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
11. PETERSON KA, SMITH CK: The DCCT findings and standards of care for diabetes. Am Fam Physician 1995; 52: 1092-8.
12. GENUTH S: Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006; 12 (Suppl. 1): 34-41.
13. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
14. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
15. GOEKOOP-RUITERMAN YP, DE VRIESBOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005; 52: 3381-90.
16. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
17. SMOLEN JS, LANDEWÉ R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
18. ALETAHA D: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008; 59: 1371-7.
19. JALAVA S, REUNANEN K: Healing of erosions in rheumatoid arthritis. Scand J Rheumatol 1982; 11: 97-100.
20. REDLICH K, GÖRTZ B, HAYER S et al.: Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004; 164: 543-55.
21. HETLAND ML, EJBJERG B, HØRSLEV-PETERSEN K et al.: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68: 384-90.
22. KIRWAN JR: The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1997; 36: 225-8.
23. KIRWAN JR: The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum 2004; 50: 1-4.
24. COHEN G, GOSSEC L, DOUGADOS M et al.: Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007; 66: 358-63.
25. SVENSSON B, SCHAUFELBERGER C, TELEMAN A, THEANDER J: Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Pharma-cotherapy. Rheumatology 2000; 39: 1031-6.
26. MOTTONEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatoid drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
27. SMOLEN JS, BREEDVELD FC, SCHIFF MH et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
28. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
29. KLINKHOFF AV, BELLAMY N, BOMBARDIER C et al.: An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988; 15: 492-4.
30. UHLIG T, KVIEN TK, PINCUS T: Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2008; 68: 972-5.
31. HART LE, TUGWELL P, BUCHANAN WW, NORMAN GR, GRACE EM, SOUTHWELL D: Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985; 12: 716-7.
32. HERNÁNDEZ-CRUZ B, CARDIEL MH: Intraobserver reliability of commonly used outcome measures in rheumatoid arthritis. Clin Exp Rheumatol 1998; 16: 459-62.
33. THOMPSON PW, HART LE, GOLDSMITH CH, SPECTOR TD, BELL MJ, RAMSDEN MF: Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991; 18: 661-5.
34. MARHADOUR T, JOUSSE-JOULIN S, CHALÈS G et al.: Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). J Rheumatol 2010; 37: 932-7.
35. PINCUS T: Advantages and limitations of quantitative measures to assess rheumatoid arthritis: joint counts, radiographs, laboratory tests, and patient questionnaires. Bull NYU Hosp Jt Dis 2006; 64: 32-9.
36. PINCUS T, YAZICI Y, SOKKA T: Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol 2007; 21: 601-28.
37. ALETAHA D, SMOLEN J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S100-S108.
38. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
39. VAN GESTEL AM, HAAGSMA CJ, VAN RIEL PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
40. PREVOO ML, VAN GESTEL AM, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LB, VAN RIEL PL: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 1101-5.
41. VANDER CRUYSSEN B, VAN LOOY S, WYNS B et al:. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-71.
42. SMOLEN JS, HAN C, BALA M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.
43. WEINBLATT ME, KEYSTONE EC, FURST DE, KAVANAUGH AF, CHARTASH EK, SEGURADO OG: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753-9.
44. VAN DER HEIJDE DM, VAN'T HOF M, VAN RIEL PL, VAN DE PUTTE LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
45. DOUGADOS M, ALETAHA D, VAN RIEL P: Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007; 25 (5 Suppl. 46): S22-9.
46. PINCUS T, MACLEAN R, YAZICI Y, HARRINGTON JT: Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 69-81.
47. PINCUS T, SOKKA T: Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S1-S9.
48. PINCUS T, SEGURADO O: Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006; 65: 820-2.
49. SOKKA T, PINCUS T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35% to 45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
50. YAZICI Y, SOKKA T, PINCUS T: Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 723-9.
51. ROSS JS, HATZIS C, SYMMANS WF, PUSZTAI L, HORTOBÁGYI GN: Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008; 13: 477-93.
52. CHEN CH, YU DT, CHOU CT: Biomarkers in spondyloarthropathies. Adv Exp Med Biol 2009; 649: 122-32.
53. LITTLE RR, SACKS DB: HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009; 16: 113-8.
54. GOLLEDGE AL, WALKER P, NORMAN PE, GOLLEDGE J: A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers 2009; 26: 181-8.
55. WOELK CH, BELIAKOVA-BETHELL N, GOICOECHEA M et al.: Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery. AIDS 2010; 24: 217-22.
56. LEITZEL K, LIPTON A, KOESTLER W et al.: Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab. J Clin Oncol 2008; 26 (20 Suppl.): Abstract 1002.
57. MERX K, MÜLLER MC, KREIL S et al.: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib and failure of interferon alpha. Leukemia 2002; 16: 1579-83.
58. PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
59. EISEN HJ, DEN MC, KLINGER TM et al.: Longitudinal monitoring of cardiac allograft recipients using peripheral blood gene expression profiling: a retrospective observational analysis of molecular testing in 19 case studies. J Heart Lung Transplant 2005; 24 (2 Suppl.): S162.
60. COSTANZO MC, COSTANZO MR, DIPCHAND A: The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-56.
61. URDEA M, KOLBERG J, WILBER J et al.: Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol 2009; 3: 748-55.
62. CHOY E, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
63. MARKATSELI TE, PAPAGORAS C, DROSOS AA: Prognostic factors for erosive rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 114-23.
64. WEYAND CM, XIE C, GORONZY JJ: Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 1992; 89: 2033-9.
65. ALAMANOS Y, DROSOS AA: Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130-6.
66. MIKULS TR, HUGHES LB, WESTFALL AO et al.: Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1529-34.
67. PLENGE RM, COTSAPAS C, DAVIES L et al.: Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39: 1477-82.
68. RAYCHAUDHURI S, REMMERS EF, LEE AT et al.: Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40: 1216-23.
69. URSUM J, VAN DER HORST IE, BOERS M, DUKMANS BA, VAN SCHAARDENBURG D: Gender differences in the presentation of complaints may affect the Disease Activity Score (DAS28). Programs and abstracts of the 2008 ACR/ARHP Annual Meeting; October 29, 2008; San Francisco, CA. Abstract 1602.
70. KLIMIUK PA, GORONZY JJ, BJÖRNSSON J, BECKENBAUGH RD, WEYAND CM: Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151: 1311-9.
71. KLAASEN R, THURLINGS RM, WIJBRANDTS CA et al.: The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009; 60: 3217-24.
72. KEELING SO, LANDEWÉ R, VAN DER HEIJDE D et al.: Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol 2007; 34: 623-33.
73. WELLS G, BECKER JC, TENG J et al.: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
74. DE RYCKE L, PEENE I, HOFFMAN IE et al.: Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63: 1587-93.
75. BRENNAN FM, MCINNES IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-45.
76. DHAOUADI T, SFAR I, ABELMOULA L et al.: Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review. Tunis Med 2007; 85: 991-8.
77. SMOLEN JS, ALETAHA D, GRISAR J, REDLICH K, STEINER G, WAGNER O: The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008; 10: 208.
78. CHAMBERS RE, MACFARLANE DG, WHICHER JT, DIEPPE PA: Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 1983; 42: 665-7.
79. KIRKPATRICK RB, EMERY JG, CONNOR JR, DODDS R, LYSKO PG, ROSENBERG M: Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997; 237: 46-54.
80. DE CEUNINCK F, GAUFILLIER S, BONNAUD A, SABATINI M, LESUR C, PASTOUREAU P: YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001; 285: 926-31.
81. LING H, RECKLIES AD: The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004; 380: 651-9.
82. KOTZIN BL, FALTA MT, CRAWFORD F et al.: Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 291-6.
83. JOHANSEN JS, STOLTENBERG M, HANSEN M et al.: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999; 38: 618-26.
84. OZGONENEL L, CETIN E, TUTUN S, TONBAKLAR P, ARAL H, GUVENEN G: The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis, Clin Rheumatol 2010; 29: 473-7.
85. TCHETVERIKOV I, LARD L, DEGROOT J et al.: Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 1094-9.
86. BUKHARI M, LUNT M, HARRISON BJ, SCOTT DG, SYMMONS DP, SILMAN AJ: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Arthritis Rheum 2002; 46: 906-12.
87. GEUSENS PP, LANDEWÉ RB, GARNERO P et al.: The ratio of circulating osteoportegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-7.
88. VAN DER HELM-VAN MIL AH, VERPOORT KN, BREEDVELD FC, TOES RE, HUIZINGA TW: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R949-58.
89. LANFANT K, MICHOT C, DAVEAU R et al.: An algorithm including the intrasynovial expression of CD20 and serum biomarkers (rheumatoid factors, anti-CCP2 and RANK-ligand) able to predict the progression of bone erosions in very early arthritis. Programs and abstracts of the 2008 ACR/ ARHP Annual Meeting; October 29, 2008; San Francisco, CA. Abstract 1605.
90. NAM J, VILLENUEVE E, EMERY P: The role of biomarkers in the management of patients with rheumatoid arthritis. Curr Rheumatol Rep 2009; 11: 371-7.
91. SYVERSEN SW, LANDEWÉ R, VAN DER HEIJDE D et al.: Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009; 36: 1769-84.
92. RIOJA I, HUGHES FJ, SHARP CH et al.: Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL12, CCL23, transformation growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58: 2257-67.
93. YOUNG-MIN, CAWSTON T, MARSHALL N et al.: Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56: 3236-47.
94. SHEN Y, KNOWLTON N, TURNER M et al.: Stepwise development of a multi-protein biomarker index of RA disease activity. Programs and abstracts of the 2009 ACR/ ARHP Annual Meeting; October 21, 2009; Philadelphia, PA. Abstract 345.
95. CAVET G, CENTOLA M, SHEN Y et al.: Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity. Presented at the 2010 EULAR Congress; Ann Rheum Dis 2010; 69 (Suppl. 3): 148.
96. CURTIS JR, HANEY D, VAN DER HELM AHM et al.: Validation of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA) in a multi-cohort study. Programs and abstracts of the 2010 ACR/ARHP Annual Meeting; November 6-11, 2010; Atlanta, GA. Abstract 2566. [Manuscript in development]
97. MAKSYMOWYCH WP, FITZGERALD O, WELLS GA et al.: Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009; 36: 1792-99.
98. MAKSYMOWYCH WP, LANDEWÉ R, TAK PP et al.: Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009; 36: 1785-91.
99. SIMON R: Development and validation of biomarker classifiers for treatment selection. J Stat Plan Inference 2008; 138: 308-20.
100. SMOLEN JS, ALETAHA D: Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther 2009; 11: 204.